About the Authors

Anne Walter

Contributed equally to this work with: Anne Walter, Apirat Chaikuad

Roles Conceptualization, Data curation, Formal analysis, Investigation, Software, Visualization, Writing – original draft

Affiliations Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig, Braunschweig, Germany, Center of Pharmaceutical Engeneering (PVZ), Technische Universität Braunschweig, Braunschweig, Germany

Apirat Chaikuad

Contributed equally to this work with: Anne Walter, Apirat Chaikuad

Roles Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Software, Writing – review & editing

Affiliations Structural Genomics Consortium, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom, Institute for Pharmaceutical Chemistry, Structural Genomics Consortium and Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany

Renate Helmer

Roles Data curation, Investigation, Methodology

Affiliation Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig, Braunschweig, Germany

Nadège Loaëc

Roles Data curation, Formal analysis, Investigation

Affiliation ManRos Therapeutics, Hôtel de Recherche, Centre de Perharidy, Roscoff, France

Lutz Preu

Roles Formal analysis, Methodology, Writing – review & editing

Affiliation Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig, Braunschweig, Germany

Ingo Ott

Roles Data curation, Formal analysis, Validation, Writing – review & editing

Affiliations Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig, Braunschweig, Germany, Center of Pharmaceutical Engeneering (PVZ), Technische Universität Braunschweig, Braunschweig, Germany

Stefan Knapp

Roles Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Writing – review & editing

Affiliations Structural Genomics Consortium, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom, Institute for Pharmaceutical Chemistry, Structural Genomics Consortium and Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany

Laurent Meijer

Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing

c.kunick@tu-braunschweig.de (CK); meijer@manros-therapeutics.com (LM)

Affiliation ManRos Therapeutics, Hôtel de Recherche, Centre de Perharidy, Roscoff, France

Conrad Kunick

Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Visualization, Writing – original draft

c.kunick@tu-braunschweig.de (CK); meijer@manros-therapeutics.com (LM)

Affiliations Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig, Braunschweig, Germany, Center of Pharmaceutical Engeneering (PVZ), Technische Universität Braunschweig, Braunschweig, Germany

Competing Interests

The authors have the following interests: NL is employed by and LM is chairman and chief scientific officer of ManRos Therapeutics (Roscoff, France). ManRos Therapeutics develops pharmacological inhibitors of disease-relevant kinases for their use against cystic fibrosis, polycystic kidney disease, Down syndrome and Alzheimer’s disease. Although ManRos is interested in DYRK1A as a potential drug target, it is focused on leucettines and structurally related compounds, and not on the scaffold described in this article (which inhibits the closely related CLKs). In particular, there is no pending patent application or approved patent filed by the authors or the company with regard to the class of compounds or its use described in the submitted article. This study was funded in part by the Structural Genomics Consortium (SGC; http://www.thesgc.org/), a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Janssen, Merck & Co., Novartis Pharma AG, Pfizer and Takeda. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.